Abstract
G A A b st ra ct s for HE-related, and all-cause hospitalizations were 0.21 and 0.45 with long term rifaximin use; both rates were significantly lower (p<0.0001, p=0.0051) compared to the corresponding rates for RCT placebo (0.72, 1.31). Safety was not adversely impacted with increased long term rifaximin exposure. Adverse event rates and the rate of change in the mean MELD scores remained stable in the long term. Mortality rates with long term rifaximin exposure were similar between all rifaximin patients (0.1) and the RCT placebo group (0.2) . Conclusions: Long term treatment with rifaximin 550 mg BID afforded continued protection from HE, reduced the hospitalization rate, and did not adversely affect safety or mortality in patients with cirrhosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
